---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-014491"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T13:26:27.492446+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q1 net loss $7.2M, DaVita invests $7.5M and amends supply deal

## Summary
- Q1 net sales $16.1M (+4.2% YoY); gross loss $0.8M vs. gross profit $0.4M last year due to inflation.
- Net loss $7.2M ($0.84/sh) compared to $7.8M ($0.91/sh) in Q1 2021; cash $9.9M at March 31.
- DaVita amended supply agreement with price increases and cost pass-through; invested $7.5M in convertible preferred stock, with potential additional $7.5M.
- Submitted supplemental data to FDA for IND to enable Phase 2 FPC home infusion trial; awaiting 30-day review.
- Partner Wanbang completed Phase 3 Triferic Dialysate enrollment in China; NDA submission targeted Q3 2023.

## SEC filing metadata
- accession: 0001628280-22-014491
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828022014491/0001628280-22-014491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828022014491/rmti-20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-014491
- JSON: https://secwatch.observer/filing/0001628280-22-014491.json
- Plain text: https://secwatch.observer/filing/0001628280-22-014491.txt

## Key facts
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported three months ended March 31, 2022 results: revenue $16.1 million.
  - Period: three months ended March 31, 2022
  - Revenue: $16.1 million
  - Result: reported results
  source text: Revenues were $16.1 million for the three months ended March 31, 2022, compared to $15.5 million for the three months ended March 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000162828022014491/0001628280-22-014491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.